Psychotropic drugs and renal failure: Translating the evidence for clinical practice

Advances in Therapy

Volumn 26, Issue 4, 2009, Pages 404-424

  Baghdady, Nour T ^a,e   Banik, Suman ^b,e   Swartz, Shari A ^c,e   McIntyre, Roger S ^d,e  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Kidney failure; Pharmacokinetics; Psychotropic agents; Renal disease

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZALEPLON; ZIPRASIDONE; ZOLPIDEM;

ANURIA; AREA UNDER THE CURVE; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EVIDENCE BASED PRACTICE; GLUCOREGULATORY DISTURBANCE; HEMODIALYSIS; HUMAN; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METABOLIC DISORDER; REVIEW; SINGLE DRUG DOSE;

ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DOPAMINE UPTAKE INHIBITORS; DRUG MONITORING; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; PATIENT SELECTION; PSYCHOTROPIC DRUGS; SAFETY; SEROTONIN AGENTS;

EID: 73449114958     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0021-x     Document Type: Review

References (65)

1. H. Sun L. Frassetto L.Z. Benet 2006 Effects of renal failure on drug transport and metabolism Pharmacol Ther. 109 1 11 16085315 10.1016/j.pharmthera. 2005.05.010 1:CAS:528:DC%2BD2MXht12ktbbM (Pubitemid 41740811)
2. F.E. Murtagh J. Addington-Hall I.J. Higginson 2007 The prevalence of symptoms in end-stage renal disease: a systematic review Adv Chronic Kidney Dis. 14 82 99 17200048 10.1053/j.ackd.2006.10.001 (Pubitemid 46014531)
3. R.S. McIntyre N.T. Baghdady S. Banik S.A. Swartz 2008 The use of psychotropic drugs in patients with impaired renal function Prim Psychiatry. 15 73 88
4. Johnson CA, Simmons WD. 2009 Dialysis of Drugs. Nephrology Pharmacy Associates. Available at: www.ckdinsights.com/downloads/Dialysis-Drugs2009.pdf. Accessed March 2009.
5. Aronoff GR, Brier ME. Prescribing drugs in renal disease. In: Brenner BM, Rector FC, eds. Brenner & Rector's The Kidney. Philadelphia, PA: 2004;2849-2870.
6. M.P. Schoerlin F.F. Horber F.J. Frey M. Mayersohn 1990 Disposition kinetics of moclobemide, a new MAOA inhibitor, in subjects with impaired renal function J Clin Pharmacol. 30 272 284 2312783 1:STN:280:DyaK3c7oslajug%3D%3D
7. M. Anttila E.A. Sotaniemi O. Pelkonen A. Rautio 2005 Marked effect of liver and kidney function on the pharmacokinetics of selegiline Clin Pharmacol Ther. 77 54 62 15637531 10.1016/j.clpt.2004.09.004 1:CAS:528:DC%2BD2MXks1Wk (Pubitemid 40075389)
8. C.C. Crone G.M. Gabriel 2004 Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations Clin Pharmacokinet. 43 361 394 15086275 10.2165/00003088-200443060-00002 1:CAS:528:DC%2BD2cXks1yht7Y%3D (Pubitemid 38594711)
9. M. Turpeinen N. Koivuviita A. Tolonen 2007 Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites Br J Clin Pharmacol. 64 165 173 17335546 10.1111/j.1365-2125.2007.02866.x 1:CAS:528:DC%2BD2sXpslGltrY%3D (Pubitemid 47063244)
10. L.M. Cohen E.G. Tessier M.J. Germain N.B. Levy 2004 Update on psychotropic medication use in renal disease Psychosomatics. 45 34 48 14709759 10.1176/appi.psy.45.1.34 1:CAS:528:DC%2BD2cXhsVamtL0%3D (Pubitemid 38082506)
11. F. Coulomb F. Ducret J.P. Laneury 2000 Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency J Clin Pharmacol. 40 482 487 10806601 10.1177/00912700022009251 1:CAS:528:DC%2BD3cXjtF2hs70%3D
12. C.J. Timmer J.M. Sitsen L.P. Delbressine 2000 Clinical pharmacokinetics of mirtazapine Clin Pharmacokinet. 38 461 474 10885584 10.2165/00003088- 200038060-00001 1:CAS:528:DC%2BD3cXkslygs7w%3D
13. A.D. Westanmo J. Gayken R. Haight 2005 Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor Am J Health Syst Pharm. 62 2481 2490 16303903 10.2146/ajhp050006 1:CAS:528:DC%2BD2MXhtlamsrnE (Pubitemid 41720564)
14. S.H. Preskorn 2004 Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor J Psychiatr Pract. 10 119 126 15330407 10.1097/00131746-200403000-00006 (Pubitemid 38405767)
15. L. Ereshefsky D. Dugan 2000 Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine Depress Anxiety. 12 suppl.1 30 44 11098412 10.1002/1520-6394(2000) 12:1+<30::AID-DA4>3.0.CO;2-G
16. M.I. Wilde P. Benfield 1995 Tianeptine A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49 411 439 1:CAS:528:DyaK2MXltleksLk%3D
17. N. Rao 2007 The clinical pharmacokinetics of escitalopram Clin Pharmacokinet. 46 281 290 17375980 10.2165/00003088-200746040-00002 1:CAS:528:DC%2BD2sXlt1Grsrs%3D (Pubitemid 46507007)
18. D.C. Hobbs 1969 Distribution and metabolism of doxepin Biochem Pharmacol. 18 1941 1954 5811627 10.1016/0006-2952(69)90290-1 1:CAS:528:DyaF1MXkvV2ksr4%3D
19. R. Rosser 1976 Depression during renal dialysis and following transplantation Proc R Soc Med. 69 832 834 794883 1:STN:280: DyaE2s%2FnvFWrtw%3D%3D
20. M.E. Ward M.N. Musa L. Bailey 1994 Clinical Pharmacokinetics of lithium J Clin Pharmacol. 34 280 285 8006194 1:CAS:528:DyaK2cXmt1Skt7w%3D
21. V.D. Schmith B. Piraino R.B. Smith P.D. Kroboth 1991 Alprazolam in end-stage renal disease: I Pharmacokinetics. J Clin Pharmacol. 31 571 579 1:STN:280:DyaK3MzkvFejuw%3D%3D
22. I. Mahmood C. Sahajwalla 1999 Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug Clin Pharmacokinet. 36 277 287 10320950 10.2165/00003088-199936040-00003 1:CAS:528:DyaK1MXjtFCku7g%3D (Pubitemid 29201736)
23. S.P. Spina M.H. Ensom 2007 Clinical pharmacokinetic monitoring of midazolam in critically ill patients Pharmacotherapy. 27 389 398 17316150 10.1592/phco.27.3.389 1:CAS:528:DC%2BD2sXjsVKks7c%3D (Pubitemid 46327906)
24. H.R. Ochs U. Oberem D.J. Greenblatt 1992 Nitrazepam clearance unimpaired in patients with renal insufficiency J Clin Psychopharmacol. 12 183 185 1629384 10.1097/00004714-199206000-00006 1:STN:280:DyaK38zjt1Oktw%3D%3D
25. D.R. Drover 2004 Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone Clin Pharmacokinet. 43 227 238 15005637 10.2165/00003088-200443040-00002 1:CAS:528:DC%2BD2cXjsVGgu78%3D (Pubitemid 38429303)
26. G. Chouinard K. Lefko-Singh E. Teboul 1999 Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone, and zolpidem Cell Mol Neurobiol. 19 533 552 10379424 10.1023/A:1006943009192 1:CAS:528: DyaK1MXktFelsrc%3D (Pubitemid 29283828)
27. M. Canal M. MacMahon J. Kwan C. Dubruc 2000 Amisulpride: kinetics in patients with renal failure European Neuropsychopharmacology. 10 suppl.3 330 331
28. U. Schmitt A. Abou El-Ela L.J. Guo 2006 Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp) J Neural Transm. 113 787 801 16252067 10.1007/s00702-005-0367-4 1:CAS:528:DC%2BD28XmtlaisL0%3D (Pubitemid 43962774)
29. F. Bressolle J. Bres A. Faure-Jeantis 1992 Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans J Pharm Sci. 81 26 32 1619566 10.1002/jps.2600810106 1:CAS:528:DyaK38XptFamug%3D%3D
30. M.C. Mauri L.S. Volonteri A. Colasanti 2007 Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response Clin Pharmacokinet. 46 359 388 17465637 10.2165/00003088-200746050-00001 1:CAS:528:DC%2BD2sXnt1WhsLk%3D (Pubitemid 46686464)
31. W.W. Shen 1999 The metabolism of atypical antipsychotic drugs: an update Ann Clin Psychiatry. 11 145 158 10482125 1:STN:280:DyaK1MvgvFymsw%3D%3D
32. P.T. Thyrum Y.W. Wong C. Yeh 2000 Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment Prog Neuropsychopharmacol Biol Psychiatry. 24 521 533 10958148 10.1016/S0278-5846(00) 00090-7 1:CAS:528:DC%2BD3cXksFais78%3D (Pubitemid 30419077)
33. F. Aweeka D. Jayesekara M. Horton 2000 The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function Br J Clin Pharmacol. 49 suppl.1 27 33 10.1046/j.1365-2125.2000.00150.x
34. R.K. Israni N. Kasbekar K. Haynes J.S. Berns 2006 Use of antiepileptic drugs in patients with kidney disease Semin Dial. 19 408 416 16970741 10.1111/j.1525-139X.2006.00195.x (Pubitemid 44393563)
35. G. Lacerda T. Krummel C. Sabourdy P. Ryvlin E. Hirsch 2006 Optimizing therapy of seizures in patients with renal or hepatic dysfunction Neurology. 67 suppl.4 28 33
36. N. Bassilios V. Launay-Vacher N. Khoury 2001 Gabapentin neurotoxicity in a chronic haemodialysis patient Nephrol Dial Transplant. 16 2112 2113 11572915 10.1093/ndt/16.10.2112 1:STN:280:DC%2BD3MrisFOlsw%3D%3D
37. Lamictal [pamphlet]. United States: GlaxoSmith-Kline; 2007.
38. D. Quinn T. Bode J.L. Reiz G.A. Donnelly A.C. Darke 2007 Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder J Clin Pharmacol. 47 760 766 17395894 10.1177/0091270007299759 1:CAS:528: DC%2BD2sXmvF2jtr0%3D (Pubitemid 46800423)
39. P. Robertson Jr. E.T. Hellriegel 2003 Clinical pharmacokinetic profile of modafinil Clin Pharmacokinet. 42 123 137 12537513 10.2165/00003088-200342020- 00002 1:CAS:528:DC%2BD3sXhsFyntbg%3D (Pubitemid 36188553)
40. K. Bezchlibnyk-Butler I. Aleksic S.H. Kennedy 2000 Citalopram - a review of pharmacological and clinical effects J Psychiatry Neurosci. 25 241 254 10863884 1:STN:280:DC%2BD3czptFWmtA%3D%3D
41. C.B. Nemeroff 2003 Overview of the safety of citalopram Psychopharmacol Bull. 37 96 121 14561952
42. N.B. Levy M. Blumenfield C.M. Beasley Jr. 1996 Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function Gen Hosp Psychiatry. 18 8 13 8666216 10.1016/0163-8343(95)00073-9 1:STN:280:DyaK283jt12jtA%3D%3D (Pubitemid 26073198)
43. Paxil CR [pamphlet]. United States: GlaxoSmith-Kline; 2008.
44. A.U. Yalcin G. Sahin M. Erol C. Bal 2002 Sertraline hydrochloride treatment for patients with hemodialysis hypotension Blood Purif. 20 150 153 11818677 10.1159/000047001 1:CAS:528:DC%2BD38Xot1Siug%3D%3D (Pubitemid 34701969)
45. K. Beliles A. Stoudemire 1998 Psychopharmacologic treatment of depression in the medically ill Psychosomatics. 39 2 19
46. S.M. Holliday P. Benfield 1995 Venlafaxine. A review of its pharmacology and therapeutic potential in depression Drugs. 49 280 294 7729333 10.2165/00003495-199549020-00010 1:CAS:528:DyaK2MXkt1Citbg%3D
47. Cymbalta [pamphlet]. United States: Eli-Lilly and Company; 2009.
48. S. Choi 2003 Nefazodone (Serzone) withdrawn because of hepatotoxicity Can Med Assoc J. 169 1187
49. Remeron - mirtazapine [pamphlet]. United States: Organon; 2008.
50. N.B. Levy 1990 Psychopharmacology in patients with renal failure Int J Psychiatry Med. 20 325 334 2086520 1:STN:280:DyaK3M3gtV2ruw%3D%3D
51. American Psychiatric Association. 2000 Practice guideline for the treatment of patients with major depressive disorder (revision) Am J Psychiatry. 157 suppl.4 1 45
52. I. Fukunishi T. Kitaoka T. Shirai 2002 Psychiatric disorders among patients undergoing hemodialysis therapy Nephron. 91 344 347 12053079 10.1159/000058418 (Pubitemid 34621709)
53. J. Sheehan A. White R. Wilson 1982 Hazards of phenothiazines in chronic renal failure Ir Med J. 75 335 6128333 1:STN:280:DyaL3s%2Fls1Wqtg%3D%3D
54. C.L. DeVane C.B. Nemeroff 2001 Clinical pharmacokinetics of quetiapine: an atypical antipsychotic Clin Pharmacokinet. 40 509 522 11510628 10.2165/00003088-200140070-00003 1:CAS:528:DC%2BD3MXms1ars78%3D
55. E. Snoeck P.A. Van M. Sack 1995 Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man Psychopharmacology (Berl). 122 223 229 10.1007/BF02246543 1:CAS:528:DyaK2MXhtVSjurnO
56. Abilify [pamphlet]. United States: Bristol-Myers Squibb Company; 2006.
57. E. Winans 2003 Aripiprazole Am J Health Syst Pharm. 60 2437 2445 14686220 1:CAS:528:DC%2BD3sXhtVWnsbjP
58. Ambien CR [pamphlet]. France: Sanofi-Aventis; 2007.
59. Sonata [pamphlet]. United States: Wyeth Pharmaceuticals; 2006.
60. C. Presne F. Fakhouri L.H. Noel 2003 Lithium-induced nephropathy: rate of progression and prognostic factors Kidney Int. 64 585 592 12846754 10.1046/j.1523-1755.2003.00096.x 1:CAS:528:DC%2BD3sXmsFyrsr8%3D (Pubitemid 36871930)
61. G. Flesch 2004 Overview of the clinical pharmacokinetics of oxcarbazepine Clin Drug Investig. 24 185 203 17516704 10.2165/00044011-200424040-00001 1:CAS:528:DC%2BD2cXjslGqt7k%3D (Pubitemid 38471365)
62. M.C. Rouan J.B. Lecaillon J. Godbillon 1994 The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites Eur J Clin Pharmacol. 47 161 167 7859804 10.1007/BF00194967 1:CAS:528: DyaK2MXis1OrsL4%3D
63. T. Watanabe H. Yoshikawa S. Yamazaki Y. Abe T. Abe 2005 Secondary renal Fanconi syndrome caused by valproate therapy Pediatr Nephrol. 20 814 817 15785938 10.1007/s00467-005-1827-7 (Pubitemid 40663170)
64. E.L. Zaki J.E. Springate 2002 Renal injury from valproic acid: case report and literature review Pediatr Neurol. 27 318 319 12435575 10.1016/S0887-8994(02)00447-2 (Pubitemid 35341708)
65. R.A. Blum T.J. Comstock D.A. Sica 1994 Pharmacokinetics of gabapentin in subjects with various degrees of renal function Clin Pharmacol Ther. 56 154 159 8062491 1:STN:280:DyaK2czktVymug%3D%3D